Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Repros (RPRX) Q1 Earnings: What's in Store for the Stock?

Repros Therapeutics Inc. RPRX is expected to report first quarter 2016 results on May 5. This Zacks Rank #2 (Buy) stock had delivered a positive earnings surprise in the fourth quarter of 2015. Let’s see how things are shaping up for the first quarter announcement.

Focus Remains on Pipeline

Repros is focused on the development of drugs for the treatment of hormonal and reproductive system disorders. However, the company suffered a huge setback last year when the FDA had issued a complete response letter (CRL) for its lead pipeline candidate, enclomiphene (testosterone deficiency). With the agency asking the company to conduct additional studies, the regulatory action does not only mean a delay, it also means additional costs.

Repros is currently conducting a phase II proof-of-concept study on enclomiphene in obese secondary hypogonadal men and is also working on gaining EU approval for the candidate. A response regarding the candidate’s approval status in the EU is expected by the fourth quarter of 2017.  

Repros’ second pipeline candidate, Proellex, is currently in phase II development for the treatment of uterine fibroids and endometriosis.

With no approved products in its portfolio, investors will be focused on Repros’ progress with its pipeline candidates as well as its cost projections.

Stocks that Warrant a Look

Here are some health care companies you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter:

The Earnings ESP for OvaScience, Inc. OVAS is +6.67% and it carries a Zacks Rank #3. The company is expected to release first-quarter results on May 5.

Jazz Pharmaceuticals JAZZ has an Earnings ESP of +6.11% and carries a Zacks Rank #3. It will be reporting first-quarter results on May 10.

Chiasma, Inc. CHMA has an Earnings ESP of +4.76% and carries a Zacks Rank #3. It is expected to report first-quarter results on Jun 13.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. http://www.zacks.com/registration/pfp/?ALERT=RPT_7BST_LP194&... blog">Click to get this free report >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
REPROS THERAPEU (RPRX): Free Stock Analysis Report
 
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report
 
CHIASMA INC (CHMA): Free Stock Analysis Report
 
OVASCIENCE (OVAS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research